COPD clinical trials in North Carolina
24 studies for COPD are looking for participants at sites in North Carolina.
Cities in North Carolina
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
- Copd01 50017, Charlotte
RecruitingPhase 2
Ages 40 to 80 · All sexes · Updated Nov 6, 2026 · NCT07725939Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
- Wake Forest School of Medicine, Salem
Recruiting
Ages 40 to 80 · All sexes · Updated Nov 5, 2026 · NCT07051707WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
- Wake Forest Baptist Medical Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07558265To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Eximia Research, Raleigh
- Carolina Research Center, Inc., Shelby
RecruitingPhase 2
Ages 40 to 85 · All sexes · Updated Oct 28, 2026 · NCT07684820A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, New Bern
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Oct 23, 2026 · NCT07082738Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- East Carolina University- Site Number : 8400102, Greenville
- All-Trials Clinical Research- Site Number : 8400008, Winston-Salem
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 23, 2026 · NCT07190222A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
- WB Contracted Clinical Research Site, Charlotte
RecruitingPhase 2
Ages 40 to 80 · All sexes · Updated Oct 23, 2026 · NCT07646587A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Salem Chest Specialists, Winston-Salem
- Southeastern Research Center, Winston-Salem
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Oct 22, 2026 · NCT07363694A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- American Health Research - Charlotte- Site Number : 8400013, Charlotte
- Atrium Health Wake Forest Baptist Pulmonary, Sleep And Allergy- Site Number : 8400004, Winston-Salem
RecruitingPhase 4
Ages 40 to 85 · All sexes · Updated Oct 20, 2026 · NCT07053423Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Duke Asthma, Allergy and Airway Center- Site Number : 8400047, Durham
- Advanced Respiratory and Sleep Medicine - Hickory- Site Number : 8400013, Hickory
- Science 37, Llc- Site Number : 8400154, Morrisville
- and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 19, 2026 · NCT07190209STRIVE Post-Market Registry Study
- Duke University Medical Center, Durham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT04302272The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
- Duke, Durham
RecruitingObservational study
Ages 40 and older · All sexes · Updated Oct 15, 2026 · NCT07612878A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Charlotte
- Research Site, Concord
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 9, 2026 · NCT06878261Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Shelby
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 5, 2026 · NCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
- GSK Investigational Site, Winston-Salem
- GSK Investigational Site, Winston-Salem
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 5, 2026 · NCT06959095A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Greensboro
- Research Site, Greenville
- Research Site, Huntersville
- and 3 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 2, 2026 · NCT06283966Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
- Southeastern Research Center, Winston-Salem
RecruitingPhase 4
Ages 60 and older · All sexes · Updated Sep 14, 2026 · NCT07816835A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, High Point
- Research Site, Kings Mountain
- Research Site, New Bern
- and 1 more
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
- Duke Asthma Allergy and Airway Center, Durham
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Aug 27, 2026 · NCT07037836Photon-counting CT in Chest Imaging
- Duke University Hospital, Durham
Recruiting
All ages · All sexes · Updated Aug 26, 2026 · NCT07031336eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Winston-Salem
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339SPIROMICS Study of Early COPD Progression (SOURCE)
- Wake Forest, Winston-Salem
RecruitingObservational studyHealthy volunteers welcome
Ages 30 to 55 · All sexes · Updated Jun 3, 2026 · NCT05033990Pulmonary Hypertension SOLAR
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 24, 2026 · NCT04778046Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Wakemed, Raleigh
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.